MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. OGN
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Organon & (OGN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Organon &
NYSE•Healthcare•Drug Manufacturers - General
$13.67+0.01(<0.01%)Pre-market
Market Cap
$3.60B
P/E
17.2x
P/S
0.6x
P/B
3.6x

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

C

How this company scores

AverageMetricSide Score: 44/100

Strongest: Cash & Earnings Quality (16/25); weakest: Growth (4/25).

Profitability15/25
Growth4/25
Balance Sheet & Red Flags9/25
Cash & Earnings Quality16/25
Strengths
High ROEConsistent free cash flowImproving leverageImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 17.2x5y range 3.6x – 17.2x
P/E 17.2x · above its 19-quarter median

Currently above its 19-quarter median.

P/S · 0.6x5y range 0.2x – 1.4x
P/S 0.6x · near its 19-quarter median

Currently near its 19-quarter median.

P/B · 3.6x5y range 1.6x – 98.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 50.2% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Price & Volume
Market Cap $3.60B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$6.13B
3Q
Q. Revenue
$1.56B
2%
TTM EBITDA
$487.00M
2Q
TTM Op. Income
$328.00M
2Q
Q. Op. Income
$212.00M
2Q
TTM Net Income
$209.00M
70%
Q. Net Income
$108.00M
26%
EPS
$0.41
27%
Shares Out.
$262.61M
7Q
$6.13B in TTM revenue declined 2.5% YoY, reaching $1.56B last quarter. TTM EBITDA of $487.00M and TTM operating income of $328.00M show growth is flowing through to the bottom line. TTM net income of $209.00M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 3 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
54.4%
2Q
EBITDA Margin
15.8%
2Q
Op. Margin
13.6%
2Q
Net Margin
6.9%
24%
Op. margin of 13.6% is up 1.4% YoY — cost efficiency is improving. Net margin at 6.9% and gross margin of 54.4% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
17.2x
379%
P/S Ratio
0.6x
46%
P/B Ratio
3.6x
4%
At 17.2x P/E, the stock trades within typical market levels. P/S of 0.6x and P/B of 3.6x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 379% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$13.18B
2Q
Cash
$1.13B
2Q
Long-Term Debt
$8.48B
3Q
Book Value
$1.01B
2Q
D/E Ratio
8.4
2Q
Debt/EBITDA
34.5
43%
With $13.18B in assets and $8.48B in long-term debt, D/E is 8.4and book value is $1.01B — elevated leverage, meaning significant financial risk in a downturn. Across the last 8 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$107.00M
51%
TTM Free Cash Flow
$567.00M
14%
FCF Margin
9.3%
12%
FCF / Net Income
2.7
2Q
TTM FCF of $567.00M on $107.00M in operating cash flow. The FCF / Net Income ratio of 2.7x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 14% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 3.6x
· below its 10-quarter median

Currently below its 10-quarter median.

Leverage Risk

Red Flag

D/E ratio is 8.4 — heavily leveraged and vulnerable to rising rates or cash flow dips.

Revenue Decline

Watch

Revenue has softened, declining in 6 quarters. Watch for further erosion.